Pegasus Biotech, Canada
CEO/Director of Process Development
Dr. Mena graduated with a chemical engineering degree from the National University of Colombia and completed his MSc and Doctorate degrees in Biotechnology at the National Autonomous University of Mexico. With more than 20 years of industry experience in both small and large biopharmaceutical companies, Dr. Mena’s career has been focused on process development, tech transfer and validation of manufacturing processes of biologics. These processes include animal and human vaccines, as well as production of monoclonal antibodies for cancer treatment and gene therapy vectors for molecular dystrophia.
As a career highlight, Dr. Mena was the CMC leader of the team who developed the first DNA vaccine (CLYNAVTM) approved in Europe (EMA) in 2016. Currently, Dr Mena is the CEO of Pegasus Biotech Inc, a CRO specializing in process and analytical development of human and animal health biologics.